Details:
The combined organization will focus on translating growth factor signaling pathways into innovative therapies including lead program, ORG-129, a gastrointestinal tract restricted ALK-5 inhibitor currently in a Phase 1 clinical trial.
Lead Product(s): ORG-129
Therapeutic Area: Gastroenterology Product Name: ORG-129
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: AgomAb Therapeutics N.V
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2021